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Background: To analyze outcome of 
retinoblastoma (RB) in resource limited settings 
Methods: In this descriptive study ,  patients of 
retinoblastoma were  treated according to UKCCSG 
RB 2005 11 protocol with main chemotherapy 
including Vincristine, Etoposide, Carboplatin and 
intrathecal Cytarabine called JOE protocol.  These 
protocols were given 3 weeks apart in the 
chemotherapy bay on outpatient basis. Total 6 
courses were given to these patients. The patients 
presenting with huge tumour with proptosis were 
offered two courses of chemotherapy (Neoadjuvant) 
before Enucleation (Removal of orbit and optic 
nerve) done as upfront Enucleation not possible 
without mutilating surgery-Exenteration. In our 
study Group A included patients who refused 
Enucleation and opted out of recommended 
treatment plan and Group B patients had 
Enucleations done and followed treatment plans 
Results:  Total 68 patients with age ranging from< 1 
to 7 years (95% <5 yrs) were included.  Thirty seven 
percent presented with bilateral retinoblastoma, fifty 
six percent with optic nerve involvement and 18% 
with brain metastasis. 30/68(44%) defaulted 
treatment, and 33/68 (49%) refused enucleation at 
diagnosis. Only 3/68(5%) had bilateral enucleation 
and 50/68(73%) unilateral enucleation with laser 
therapy in 7/68(10%).Total 52% completed treatment, 
26% left against medical advice and 9% expired due 
to metastatic and progressive disease and sepsis. 9/68 
(13%) patients relapsed. Neoadjuvant chemotherapy 
was given in 59% with 61% of total abandonment 
and 50% of deaths in this group. The number of 
bilateral RB was increased to 37% as compared to 
18%.Abandonment increased from 13% to 26%.  
Conclusion:  Mortality of 9% can be reduced by 
early diagnosis and early treatment. Management of 
RB needs efficient multidisciplinary team and long 
term sustainable  programs to improve survival. The 
Neoadjuvant group needs extensive follow up and 
counselling to decrease abandonment. 
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While Retinoblastoma is highly curable in developed 
countries, the outcome is still dismal in Pakistan. 
Retinoblastoma is the most common primary 
intraocular malignancy in paediatric population. 
When Retinoblastoma is diagnosed in early intraocular 
stages the probability of disease free survival in good 
centers have been 80-90% with Enucleation of the 
affected eye, a simple surgical procedure usually 
curative in intraocular retinoblastoma.1 RB is one of 
the more common malignancies in paediatric oncology 
in developing countries. The annual incidence of 
retinoblastoma in USA is 3.8 cases per million and 
higher in Africa up to 20 cases per million children 
under 5 with survival rates upto 30%  and up to seven 
times that of Western Europe (4.1 per million) in Brazil 
and Mexico evidenced by population based studies 
and cancer registries data. 2,3 
In developed countries, sophisticated conservative 
strategies are used to preserve eyes with useful vision 
without changing the survival.  Although these 
outcomes are very encouraging but the majority of the 
8,000 children diagnosed with RB worldwide have not 
benefited from these trends. In developing countries 
the diagnosis is made quite late with extraocular 
metastasis therefore ocular and patient survival rates 
are much lower than in developed countries as it is 
difficult to treat even with most sophisticated and 
intense regimens.4 These cases depict longer lag times 
from the onset of symptoms to the final diagnosis 
made.5 Another critical factor greatly influencing the 
outcome is therapy refusal by parents against 
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recommended medical advice, however late diagnosis 
is given more attention than families opting out of 
treatment in literature.6 Therefore survival of these 
children in developing countries is affected by 
socioeconomic and cultural factors causing delays 
leading to extra-ocular dissemination than by the 
unavailability of advanced treatments as described for 
other childhood malignancies as ALL or other solid 
tumors.7 
In developing countries, multiple factors including late 
referrals due to lack of parental education and 
awareness among health professionals for early signs  
resulting  in delayed diagnosis with extra-ocular 
presentation in 50 % of cases along with refusal of 
Enucleation and incomplete treatment. To improve 
survival and vision it is imperative to improve the 
referral systems with increased awareness of doctors 
and parents by community outreach program.8 
 
Patients and Methods 
In this descriptive study , performed in department of 
Paediatric Haematology/Oncology of the Children’s 
Hospital & the Institute of Child Health Lahore from 
June 2013 to December 2015, patients of 
retinoblastoma were included. Patients were treated 
according to UKCCSG RB 2005 11 protocol with main 
chemotherapy including Vincristine, Etoposide, 
carboplatin and intrathecal Cytarabine called JOE 
protocol. Doses calculated according to body surface 
area. These protocols were given 3 weeks apart in the 
chemotherapy bay on outpatient basis. Total 6 courses 
were given to these patients. The patients presenting 
with huge tumor with proptosis were offered two 
courses of chemotherapy (Neoadjuvant) before 
Enucleation (Removal of orbit and optic nerve) done 
as upfront Enucleation not possible without mutilating 
surgery-Exenteration. In our study Group A includes 
patients who refused Enucleation and opted out of 
recommended treatment plan and Group B patients 
had Enucleations done and followed treatment plans. 
  
Results 
Total 68 patients with age ranging from< 1 to 7 years 
(95% <5 yrs) were included (Table 1). M: F Ratio was 
1:1. These patients mainly presented with leukocoria 
of affected eye, squint and proptosis and huge 
disfiguring tumors or fungating masses along with 
loss of vision of the affected eye. (Figure 1& 2). Thirty 
seven percent ( 25/68) presented with bilateral 
Retinoblastoma and 38/68 (56%) with optic nerve 
involvement (Figure B & D) and brain metastasis 
12/68(18%). (Figure 3-6).30/68(44%) defaulter 
treatment (Table 2), and 33/68 (49%) refused 
Enucleation at diagnosis (Table 3). Only 3/68(5%) had 
bilateral Enucleation and 50/68(73%) unilateral 
Enucleation with laser therapy in 7/68(10%).Total 
35/68 (52%) have completed treatment, 18/68 (26%) 
left against medical advice (LAMA) and 6/68 (9%) 
expired due to metastatic and progressive disease and 
sepsis. 9/68 (13%) patients relapsed (Table 4). 
Neoadjuvant chemotherapy was given in 40/68 (59%) 
with 61% of total abandonment and 50% of deaths in 
this group. When compared with the previous study 
presented in SIOP 2014 mortality decreased from 18 to 
9% and defaulter trend decreased from 66% to 44% 
(30/68) and Neoadjuvant chemotherapy used in 59% 
cases as compared to 54%.The number of bilateral RB 
was increased to 25/68(37%) as compared to 
10/56(18%).Abandonment increased from 13% to 26%.  
 
Table1: Age distribution 
Age (years) < 1r  1-5  >5  
Number 20 44 4 
% 30% 65% 5% 
<5 Years=95% 
 
Table2: Pattern of treatment course 







30(44%) 38(56%) 0.000 
p-value<0.05 is statistically significant 
Table 3: Refusal of enucleation 







33 (49%) 35 (51%) 0.002 
p-value<0.05 is statistically significant 
Table4: Outcome of Retinoblastoma 
 LAMA Expired Treatment 
Completed 
Relapsed 
Number 18 6 38 5 













Figure 2: Leukocoria 
Right Eye 

































 In present study only 29% cases presented before one 
year of age and more than two thirds duration of 
symptoms longer than three months before diagnosis 
(lag period) significant predictors for presence of 
pathological high risk factors (HRF) indication need of 
adjuvant chemotherapy and radiotherapy. The mean 
age of diagnosis in Western children is reported as 18 
months and median age at diagnosis in Indian 
children was 24 months.9 Delayed diagnosis is one of 
the two most important causes of advanced disease at 
presentation in developing countries as well as 
diagnosis at later ages as compared to the developed 
countries.10The importance of lag time between 
presentation of symptoms and diagnosis with outcome 
modification was firstly emphasized by Brazilian 
researchers.10 .This can be encouraged in LIC(Low 
Income Countries) where majority of patients present  
with advanced disease and high eventual mortality as 
in MIC/ developed countries survival increases up to 
80% so they are focusing  more on eye and vision 
preservation by doing screening of familial 
Retinoblastoma cases which is still as low as 23% in 
developing countries.11,12 
The second most important point in our study is 
behavior of families opting out of recommended 
treatment whether chemotherapy or Enucleation even 
if timely diagnosis is made in good centers.6In our 
study 49% refused Enucleation at diagnosis and 44% 
defaulted chemotherapy with overall poor 
survival.64% received chemotherapy at delayed 
schedules after Enucleations and 26% cases didn’t 
receive any treatment. As these patients were not 
treated in time with surgery, chemotherapy and 
radiotherapy they relapsed (13%) as compared to 3% 
in MIC   and died (9%) due to progressive disease.  13 
So in our study 52 % cases able to complete therapy 
successfully and they are well but need further follow 
up and monitoring, the rest 48 % eventually expired 
due to Retinoblastoma. Though estimated survival rate 
in LIC is 30 % with 35% cases presenting in advanced 
stages and 40% refusing Enucleation and further 
management in Asia, Africa and Central America.14 In 
MIC(Middle Income Countries)  Estimated survival is 
60-75% cases with 10-15 % cases presenting in 
advanced stages and only 30% estimated cases opting 
out of treatment while this trend is only 1% in HIC 
(High Income Countries with 95% estimated survival 
rate with 3% cases presenting in advanced stages at 
presentation.14 
 In present  study optic nerve involvement was present 
in  56% lower than in African Countries 68% to 78%  
but higher than in France 45% (1977-1990)but much 
lesser currently(3%)  with increased risk of orbital and 
metastatic diseas. 2,19 .  In India there was 17% 
retrolaminar optic nerve involvement and 9% 
extrascleral and optic nerve transection invasion 
classified as microscopic residual disease and in 326 
eyes over a period of 5 years and with median age of 
presentation 2 years requiring postoperative adjuvant 
chemotherapy and radiotherapy.9 
Neoadjuvant chemotherapy was given in 59% cases 
but data showed increased abandonment and deaths 
in this group though there are good results with up to 
70% disease free survival with different chemotherapy 
regimens using etopside, ifosfamide and 
anthracyclines and up to 56% survival with less 
intensive chemotherapy in LIC like Mali.15, 17 In 
advanced cases involving CNs and distant metastases  
routine chemotherapy and radiotherapy gives dismal 
results with eventual relapse and ultimately death in 
LIC and adequate palliation should be provided for 
these children  but unfortunately is not adequately 
available in many centers.18 
Figure 3.T1W MRI brain 
with contrast, axial 
section Through orbits 
demonstrate menigeal 
metastasis  
Figure 4: T2W MRI brain, 
hypointense mass in Left 
orbit with left optic nerve 
involvement section 




Figure 6: Multiechoic MRI 
demonstrates 
heterogenous signal in left 
orbit with left optic nerve 
involvement 
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While Eye conserving treatment in developed 
countries is the standard of care , we are struggling 
hard to save these children as they present very late 
and then they don’t adhere to the planned treatment  
A more focus on how to improve acceptance of 
families for life saving procedure of enucleation and 
compliance of treatment and improved palliative and 
supportive care services as high intensity 
chemotherapy regimens are required to treat them and 
provision of adequate facilities for EBRT (external 
Beam Radiotherapy).14, 20 As disease free survival in 
LIC is <50% with >30 % presenting g with metastatic 
disease at diagnosis due to mainly sociocultural factors 
like treatment nonadherence and late diagnosis partly 
due to paucity of efficient multidisciplinary treatment 
centers it’s the need of time to establish awareness 
campaigns for early referrals. Early diagnosis 
campaigns, programs to prevent treatment 
nonadherence and twinning programs with high-
income countries to increase survival like St.Jude 
Children Research Hospital  USA.14 The need of 
multidisciplinary treatment centers  in developing 
countries cannot be overemphasized for better 
management  with significant roles of highly trained 
histopathologists, critical for identifying high risk 
patients as if missed and not given adjuvant 
chemotherapy might eventually progress  and die of 
metastatic retinoblastoma.14 Trained  radiologist, 
radiation oncologist and paediatric oncologist with 
improved supportive care services while giving 
intensive chemotherapy regimens  and palliative care 
services are essential  . 21,22 
Conclusion 
Mortality of 9% can be reduced by early diagnosis and 
early treatment.  The Neoadjuvant group needs 
extensive follow up and counseling to decrease 
abandonment. 
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